- We’ve identified compounds that inhibit P. gingivalis, a pathogen linked to atherosclerotic plaque.
- Validated in animal models, these compounds significantly reduce plaque formation.
- An FDA-approved compound, available for immediate application, has shown promise in atherosclerosis treatment.
- Additional compounds are under evaluation for pharmacological development.
- Compounds effective in controlling P. gingivalis biofilm open possibilities in treating periodontitis.
Frequently Asked Question
What is the focus of Magnacor Therapeutics’ research?
Magnacor is dedicated to developing a novel class of drugs that target atherosclerosis and other chronic inflammatory diseases. Our research specifically addresses cardiovascular disease, aiming to provide therapies for patients with critical unmet medical needs.
What stage is Magnacor Therapeutics in its research and development process?
We have successfully completed animal trials that showed promising results in reducing atherosclerotic plaques. Currently, we are preparing for human trials to further test our therapies with the goal of bringing life-changing treatments to patients worldwide.
How is your approach to cardiovascular disease treatment different?
Our approach focuses on addressing bacterial pathogens associated with atherosclerotic plaques, a factor largely overlooked in traditional treatments. By targeting these intracellular pathogens, we aim to reduce inflammation and atherosclerotic plaque formation, providing a more comprehensive solution to cardiovascular disease.
How can I get involved with Magnacor Therapeutics’ mission?
We welcome interest from potential investors, collaborators, and partners who are passionate about advancing cardiovascular care. Reach out via our Contact Us page to explore opportunities for investment, licensing, or collaboration.